Drug Profile
RD 42217
Alternative Names: RD4-2217Latest Information Update: 23 Apr 2003
Price :
$50
*
At a glance
- Originator Rational Drug Design Laboratories
- Class Antiretrovirals
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections